VOLUME 35 NUMBER 3 MARCH 2017 nature biotechnology l e t t e r s Efforts to develop gene therapies for hearing loss have been hampered by the lack of safe, efficient, and clinically relevant delivery modalities 1,2 . Here we demonstrate the safety and efficiency of Anc80L65, a rationally designed synthetic vector 3 , for transgene delivery to the mouse cochlea. Ex vivo transduction of mouse organotypic explants identified Anc80L65 from a set of other adeno-associated virus (AAV) vectors as a potent vector for the cochlear cell targets. Round window membrane injection resulted in highly efficient transduction of inner and outer hair cells in mice, a substantial improvement over conventional AAV vectors. Anc80L65 round window injection was well tolerated, as indicated by sensory cell function, hearing and vestibular function, and immunologic parameters. The ability of Anc80L65 to target outer hair cells at high rates, a requirement for restoration of complex auditory function, may enable future gene therapies for hearing and balance disorders.
l e t t e r s
Efforts to develop gene therapies for hearing loss have been hampered by the lack of safe, efficient, and clinically relevant delivery modalities 1, 2 . Here we demonstrate the safety and efficiency of Anc80L65, a rationally designed synthetic vector 3 , for transgene delivery to the mouse cochlea. Ex vivo transduction of mouse organotypic explants identified Anc80L65 from a set of other adeno-associated virus (AAV) vectors as a potent vector for the cochlear cell targets. Round window membrane injection resulted in highly efficient transduction of inner and outer hair cells in mice, a substantial improvement over conventional AAV vectors. Anc80L65 round window injection was well tolerated, as indicated by sensory cell function, hearing and vestibular function, and immunologic parameters. The ability of Anc80L65 to target outer hair cells at high rates, a requirement for restoration of complex auditory function, may enable future gene therapies for hearing and balance disorders.
Hearing loss is the most common sensory disorder worldwide, with half of prelingual deafness due to genetic causes 4 . More than 300 genetic loci linked to hereditary hearing loss and >100 causative genes have been identified 4, 5 . Age-related hearing impairment affects the quality of life of over a quarter of individuals >65 years old. While medication history and noise exposure are known contributing factors to presbycusis, several genetic factors have been identified 6 . Sensory cells of the adult mammalian cochlea lack the capacity for self-renewal 7, 8 . Current therapies for hearing loss employ various strategies depending on the level and exact position of impairment, including sound amplification (hearing aids), enhanced sound transmission (middle ear prostheses/active implants), and direct neuronal stimulation (cochlear implants) to compensate for permanent damage to primary sensory hair cells or to spiral ganglion neurons, which form the auditory nerve and relay acoustic information to the brain 2 .
These approaches, while potentially transformative, remain far from optimal in restoring complex hearing function and may have deficiencies in frequency sensitivity, natural sound perception, and speech discrimination in noisy environments.
Therapeutic gene transfer to the cochlea could improve on the current standard of care for both genetic 1, 2, [9] [10] [11] [12] [13] and age-related or environmentally induced hearing loss 1, 2, 12, 13 . This approach would require the development of methods for safe, efficient delivery of transgene constructs to the relevant cell types in the organ of Corti in the cochlea. The organ of Corti includes two classes of sensory hair cells: inner hair cells (IHCs), which convert mechanical information carried by sound into electrical signals transmitted to neuronal structures, and outer hair cells (OHCs), which amplify and tune the cochlear response, a process required for complex hearing function 14 . Other potential targets in the inner ear include spiral ganglion neurons, columnar cells of the spiral limbus, which are important for the maintenance of the adjacent tectorial membrane [15] [16] [17] , and supporting cells, which have protective functions and can be triggered to transdifferentiate into hair cells up until an early neonatal stage [18] [19] [20] [21] .
Direct access to hair cells for gene therapy may be achievable through vector injection into the cochlear duct. However, interventions that alter the delicate high-potassium endolymph fluid in the duct could disrupt the endocochlear potential, leading to damage of the sensory cells and irreversible hearing loss. The perilymphfilled spaces surrounding the cochlear duct, scala tympani, and scala vestibuli can be accessed from the middle ear, either through the oval window membrane or the round window membrane (RWM). The RWM, which is the only non-bony opening into the inner ear, is relatively easy to access in many animal models, and administration of viral vector using this route has been well tolerated 10, 11, 22 . In humans, cochlear implant placement routinely relies on surgical electrode insertion through the RWM 23 . l e t t e r s Several non-viral 24, 25 and viral (e.g., adenovirus, AAV, lentivirus, herpes simplex virus I, vaccinia virus) gene transfer vectors have been tested in the cochlea, often with only transient or suboptimal gene transfer as a result 1 . Only adenovirus has progressed to a clinical program (NCT02132130) 2, 26 . For other target organs, such as the liver and the retina, AAV has shown clinical efficacy and safety in hemophilia B 27 , two types of inherited blindness 28, 29 , and familial lipoprotein lipase deficiency 30 . Previous studies of AAV serotypes for in vivo inner ear injection via different routes of administration highlighted the difficulties in targeting OHCs, particularly via RWM injection 31 , and resulted in only partial correction of hearing in mouse models of inherited deafness [9] [10] [11] . To identify vectors that target both IHCs and OHCs with high efficiency, we evaluated natural AAVs alongside a recently developed synthetic AAV called Anc80L65. This in silico-designed particle approximates the ancestral state of the viral capsid within the lineage of the commonly used AAV serotypes 1, 2, 6, 8, and 9, and is a structurally stable and antigenically distinct AAV 3 . Anc80L65 was shown to be a potent gene transfer agent in liver, retina, and muscle 3 , which led us to characterize its tropism in the inner ear in vivo.
In a first selection, we incubated iodixanol-purified high-titer preparations of single-stranded AAV1, 2, 6, 8, 9, and Anc80L65 encoding eGFP driven from the cytomegalovirus immediate-early (CMV) promoter, at equal doses of 10 10 genome-containing (GC) particles, with organotypic cochlear explants from C57BL/6 or CBA/CaJ mice harvested at postnatal day (P) P4. We performed histology of the inoculated cochleas after 2 d of vector exposure. eGFP expression was qualitatively brighter in cochlear cultures exposed to Anc80L65, with expression apparent in many cochlear cell types ( Fig. 1 and Supplementary Fig. 1 ). Morphometric quantitative analysis was performed to determine transduction rates for IHCs, OHCs, supporting cells, limbus cells, and spiral ganglion neurons. For IHCs and OHCs, vector transduction efficiency was quantified as the percentage of eGFP-positive cells in representative 100-µm sections taken from the basal and apical regions of the cochlea. Anc80L65 targeted IHCs and OHCs at efficiencies of 60-100% on average in apical and basal regions of both mouse strains tested (Fig. 1h,i and Supplementary Fig. 1g,h) . Anc80L65 showed consistently and qualitatively brighter IHC and OHC eGFP expression as compared to AAV2 ( Fig. 1 and Supplementary Fig. 1) .
To control for possible differences between the AAV serotypes in the onset of transgene expression, which could lead to an underestimate of expression at the 2-d time point, we repeated the above experiment with a new set of cochleas and maintained the culture for an additional 5 d (referred to as 48 h + 5 d). A similar pattern of expression in IHCs and OHCs was observed in this longer-term study for AAV2 and Anc80L65 (Fig. 1j,k and Supplementary Fig. 1i,j) . Moderate increases in expression for AAV6, 8, and 9 in CBA/CaJ mice, particularly at the basal turn ( Fig. 1j,k, and Supplementary  Fig. 1i,j) , were noted. Other cell types were targeted by all serotypes, with limbus being more permissive than supporting cells, followed by spinal ganglion neurons (Supplementary Figs. 2-4) . Consistently, Anc80L65 transduction yielded higher efficiencies and stronger expression, evidenced by brighter eGFP fluorescence ( Fig. 1 and Supplementary Figs. 1-4) .
Next, we evaluated the tropism and gene transfer efficiency of AAV1, 2, 6, 8, and Anc80L65 in vivo, using a protocol that is therapeutically relevant with respect to vector pharmacokinetics, anatomical and cellular barriers to transduction, and surgical approach. C57BL/6 animals were injected at P1 and cochleas were harvested, fixed and stained at P10 (Fig. 2) . Consistent with prior reports [9] [10] [11] 32 , AAV1 transduced IHCs with moderate to high efficiency ( Fig. 2a,b) . Our results indicated that AAV2, 6, and 8 target low numbers of IHCs ( Fig. 2a,b) . Also, consistent with prior reports, transduction of OHCs was minimal (<5%) for all conventional AAV serotypes tested. In contrast, Anc80L65 transduced nearly 100% of IHCs and ~90% of OHCs ( Fig. 2a-c) at a 20-fold (for AAV1) to threefold (for AAV2) lower dose. Transduction at equal doses of 1.36 × 10 12 GC for all serotypes resulted in substantial IHC and OHC transduction for Anc80L65, but minimal IHC targeting for AAV1, 2, and 8, and none l e t t e r s noted in OHCs as observed by live-cell imaging by epifluorescence microscopy (Fig. 3c,d) .
The Anc80L65-transduced samples were subsequently fixed, stained and imaged, revealing a dose-dependence of hair cell transduction (Fig. 3e) . The unprecedented high level of OHC targeting ( Fig. 2c  and 3 ) suggests that the transduction mechanism of Anc80L65 is qualitatively different from that of other AAVs. We found similar levels of Anc80L65 transduction throughout the cochlea from base to apex in a total of three Anc80L65-injected mice ( Fig. 2a-c) . Low-magnification views of the cochlear apex ( Fig. 3a) showed strong eGFP expression far from the injection site. High-magnification images of the base reveal 100% IHC and 95% OHC transduction (Fig. 3b) .
In some animals, we found robust eGFP expression in the contralateral uninjected ear (Supplementary Fig. 5 ). In mice, the cochlear aqueduct is patent, providing a fluid path from the cochlear perilymph into the cerebrospinal fluid, the contralateral aqueduct and into the contralateral cochlea. We therefore investigated whether Anc80L65-eGFP injected via the RWM transduced neurons in the brain. Cross-sections of the cerebellum revealed strong eGFP expression in cerebellar Purkinje neurons ( Supplementary Fig. 6a,b) .
We further investigated whether Anc80L65 RWM injection led to a humoral response to the vector capsid and found that low levels of neutralizing antibodies to the vector were detectable in injected mice in serum, but not in cerebrospinal fluid, at the level of sensitivity of the assay and sampling (Supplementary Fig. 6c ).
To determine whether Anc80L65-eGFP had any consequences for cellular function, we recorded sensory transduction currents from both IHCs and OHCs. Representative currents evoked by hair bundle deflections from P7 OHCs and P35 IHCs revealed no differences in amplitude, sensitivity, or kinetics between eGFP-positive and eGFP-negative control cells (Fig. 2d) . We recorded from 51 eGFP-positive and 52 eGFP-negative hair cells from all regions of the cochlea 1-5 weeks after exposure to Anc80L65. Responses were indistinguishable from wildtype in all cases ( Fig. 2e) , which confirmed that Anc80L65 transduction had no detrimental effects on sensory cell function.
To evaluate systems-level function, we measured auditory brainstem responses (ABRs) from four Anc80L65-injected ears and four uninjected ears. Minimal sound thresholds required to evoke ABRs were plotted ( Fig. 2f ) and revealed no difference in threshold between injected and uninjected ears. Histological analysis showed strong eGFP fluorescence in all four injected ears (data not shown). In one additional case, there were no eGFP-positive cells and ABR thresholds were elevated ( Fig. 2f) , suggesting that the injection failed and that the needle may have breached the cochlear duct and caused permanent damage.
As a final test of auditory function, we measured distortion product otoacoustic emissions (DPOAEs), which reflect proper cochlear amplification and tuning and are a sensitive measure of OHC viability 17 . Despite robust OHC transduction by Anc80L65-eGFP, we found no difference in DPOAE thresholds relative to uninjected control ears (Fig. 2g) . Thus, data from all three measures-single-cell physiology, ABRs, and DPOAEs-indicate that RWM injection, Anc80L65 transduction, and eGFP expression in IHCs and OHCs are safe and do not harm auditory function. Frequency (kHz) 
Since the perilymphatic solutions of the cochlea are continuous with those of the vestibular labyrinth, we wondered whether Anc80L65-eGFP injected via the cochlear RWM would transduce vestibular sensory organs. Indeed, whole-mounts of vestibular epithelia revealed robust eGFP expression in both type I and type II hair cells of the utricle, a vestibular organ sensitive to gravity and linear head movements, and in the semicircular canals, which are sensitive to rotational head movements (Fig. 4a,b) . To address the safety concern that Anc80L65 transduction may affect balance, we used the rotarod test for vestibular function. Injected mice performed similarly to uninjected controls (P = 1.00, Supplementary Fig. 7) .
Some forms of genetic deafness also cause vestibular dysfunction, and Anc80L65 may be a useful vector for gene delivery into human vestibular organs. To investigate this possibility, we harvested human vestibular epithelia from four adult patients undergoing resection of vestibular schwannoma tumors and placed the sensory epithelium in culture as previously described 33 . AAV-transduced samples showed strong eGFP fluorescence throughout the human vestibular epithelium in both hair cells and supporting cells (Fig. 4c) . In a highmagnification view of an epithelium counterstained with Myo7A, 83% (19/23) of Myo7A-positive hair cells were also eGFP-positive, suggesting that Anc80L65 can transduce both mouse and human hair cells efficiently (Fig. 4d) .
Our finding that Anc80L65 transduces OHCs with high efficiency overcomes the low transduction rates that have limited development of cochlear gene therapy using conventional AAV serotypes. Thus, Anc80L65 may provide a valuable approach for gene delivery to human IHCs and OHCs, as well as to other inner ear cell types that are compromised by genetic hearing and balance disorders. Previous work has shown that Anc80L65 has an analogous safety profile in mouse and nonhuman primate after systemic injection, and is antigenically distinct from circulating AAVs, providing a potential benefit in terms of pre-existing immunity, which limits the efficacy of conventional AAV vectors 4 .
Further validation of Anc80L65 as a gene transfer vector for use in human inner ear gene therapy will require targeting-efficiency studies in large-animal models; additional exploration of the window of opportunity for therapeutic intervention; and pharmacology and toxicology studies to investigate the safety of Anc80L65 upon cochlear administration. Given the promiscuity of expression of AAV, including Anc80L65, additional methods to maximize specificity and minimize biodistribution should be considered to limit expression outside of the therapeutic cochlear cell target. Considering that nonsyndromic auditory and vestibular dysfunction can be caused by dominant or recessive mutations in >100 genes, Anc80L65 may accelerate the development of novel gene therapy strategies for a wide range of inner ear disorders.
METHods
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. In brief, murine temporal bones were harvested after decapitation and the cochlea was dissected to culture as organotypic explants connected to the spiral ganglion neuron region. Two specimens were obtained per cochlea, one ("apical") consisting of the lower apical and one ("basal") of the upper basal turn. For each serotype, a minimum of 3 (CBA/CaJ, 48 h), 2 (CBA/CaJ, 48 h + 5 d), 3 (C57BL/6, 48 h), 2 (C57BL/6, 48 h + 5 d) basal and apical specimens were inoculated (unless otherwise noted). Specimens were excluded if cochlear morphology was not retained during the culture. Sample numbers were chosen to inform on the variability of transduction and to provide a basis for selection for further in vivo evaluation. Explants were incubated with culture medium (98% Dulbecco's Modified Eagle Medium (DMEM), 1% ampicillin, and 1% N2 supplement during the first 12 h, plus 1% FBS) and 10 10 GC AAV for 48 h in 50 µl. For the 48 h + 5 d condition, the medium with AAV was replaced with fresh media without AAV for an additional 5 d. Human vestibular epithelia from utricles obtained from four consented, adult patients undergoing vestibular schwannoma tumor resection were cultured as previously described 33 , exposed to 10 10 GC AAV for 24 h, and maintained in culture for 10 d, after which the tissue was fixed and stained with phalloidin and imaged. Studies were approved by the Surrey Borders NRES Committee London (Health Research Authority) under reference number 11/LO/0475.
In vivo injections.
Mouse pups (P0 to P2) were injected via the round window membrane (RWM) using beveled glass microinjection pipettes. Pipettes were pulled from capillary glass (WPI, Sarasota, FL) on a P-2000 pipette puller (Sutter Instrument, Novato, CA) and were beveled (~20 µm tip diameter at a 28° angle) using a micropipette beveler (Sutter Instrument, Novato, CA). EMLA cream (lidocaine 2.5% and prilocaine 2.5%) was applied externally for analgesia using sterile swabs to cover the surgical site (left mastoid prominence). Body temperature was maintained on a 38 °C warming pad before surgery. Pups were anesthetized by rapid induction of hypothermia via immersion in ice/water for 2-3 min until loss of consciousness, and this state was maintained on a cooling platform for 5-10 min during the surgery. The surgical site was disinfected by scrubbing with betadine and wiping with 70% ethanol in repetition three times. A post-auricular incision was made to expose the transparent otic bulla, a micropipette was advanced manually through the bulla and overlying fascia, and the RWM was penetrated by the tip of the micropipette. Approximately 1 µL of virus at the available concentration was injected unilaterally within
